ABI-0299

ABI-0299 is a humanized monoclonal antibody designed to target and neutralize tumor necrosis factor-alpha (TNF-α), a key pro-inflammatory cytokine involved in the pathogenesis of various autoimmune and inflammatory conditions. Developed by Abivax, the candidate is primarily intended for the treatment of inflammatory bowel diseases, specifically ulcerative colitis. ABI-0299 is engineered for high affinity and potency, aiming to provide a superior therapeutic profile compared to first-generation anti-TNF agents like adalimumab or infliximab. While it represents a promising next-generation biologic within an established class, Abivax has strategically prioritized its lead candidate, obefazimod, and is currently seeking partnerships to advance ABI-0299 through clinical development.